Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BeOne Medicines Ltd. Director's Dealing 2025

Jun 12, 2025

30073_dirs_2025-06-12_6c2faf7a-74d3-4e64-96f6-2c0dd5371681.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeOne Medicines Ltd. (ONC)
CIK: 0001651308
Period of Report: 2025-06-10

Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-06-10 Ordinary Shares A 98696 Acquired 5180861 Direct
2025-06-10 American Depositary Shares M 41760 $6.50 Acquired 41760 Direct
2025-06-10 American Depositary Shares S 2901 $261.2041 Disposed 38859 Direct
2025-06-10 American Depositary Shares S 15878 $262.2032 Disposed 22981 Direct
2025-06-10 American Depositary Shares S 16094 $263.1727 Disposed 6887 Direct
2025-06-10 American Depositary Shares S 6787 $264.0804 Disposed 100 Direct
2025-06-10 American Depositary Shares S 100 $264.85 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-06-10 Share Option (Right to Buy) $20.26 A 185796 Acquired 2035-06-09 Ordinary Shares (185796) Direct
2025-06-10 Share Option (Right to Buy) $0.50 M 542880 Disposed 2025-07-19 Ordinary Shares (542880) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 1025063 Indirect
Ordinary Shares 3953100 Indirect
Ordinary Shares 50 Indirect

Footnotes

F1: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F2: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

F4: These securities are held by the spouse of the Reporting Person.

F5: Each American Depositary Share represents 13 Ordinary Shares.

F6: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.66 to $261.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.66 to $262.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.66 to $263.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.66 to $264.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F11: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F12: These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject
to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F13: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service.